Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue SUPPL. 1, 2011, Pages

  Sgouros, George ^a   Hobbs, Robert F ^a   Atkins, Francis B ^b   Van Nostrand, Douglas ^b   Ladenson, Paul W ^a   Wahl, Richard L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Positron emission tomography; Radioiodine therapy; Three dimensional radiobiological dosimetry; Thyroid cancer

Indexed keywords

IODINE 124; IODINE 131;

COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; HUMAN; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE DISTRIBUTION; RADIOBIOLOGY; RADIOSENSITIVITY; REVIEW; THREE DIMENSIONAL RADIOBIOLOGICAL DOSIMETRY; THYROID CANCER;

HUMANS; IMAGING, THREE-DIMENSIONAL; IODINE RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; SOFTWARE; THYROID NEOPLASMS;

EID: 79957962933     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1769-1     Document Type: Review

References (35)

1. Hellman S, Devita VT, Rosenberg SA. Principles of cancer management: radiation therapy. Cancer: principles & practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 265-88.
2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer DS Cooper GM Doherty BR Haugen RT Kloos SL Lee SJ Mandel EL Mazzaferri B McIver F Pacini M Schlumberger SI Sherman DL Steward RM Tuttle 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 19 11 1167 1214 19860577 10.1089/thy.2009.0110
3. D Van Nostrand F Atkins F Yeganeh E Acio R Bursaw L Wartofsky 2002 Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma Thyroid 12 2 121 134 11916281 10.1089/105072502753522356 (Pubitemid 34218137)
4. JP Holst KD Burman F Atkins JG Umans J Jonklaas 2005 Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis Thyroid 15 12 1321 1331 16405403 10.1089/thy.2005.15.1321 1:CAS:528:DC%2BD28XkvFyrtw%3D%3D (Pubitemid 43132677)
5. AA Driedger S Quirk TJ McDonald S Ledger D Gray W Wall J Yoo 2006 A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure Clin Nucl Med 31 8 454 457 16855429 10.1097/01.rlu.0000227013. 36421.ce 1:STN:280:DC%2BD28vmt12nug%3D%3D (Pubitemid 44315493)
6. G Sgouros KS Kolbert A Sheikh KS Pentlow EF Mun A Barth RJ Robbins SM Larson 2004 Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software J Nucl Med 45 8 1366 1372 15299063 1:CAS:528:DC%2BD2cXnsFSmu70%3D (Pubitemid 47618537)
7. W Jentzen RF Hobbs A Stahl J Knust G Sgouros A Bockisch 2010 Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer Eur J Nucl Med Mol Imaging 37 5 884 895 20069293 10.1007/s00259-009-1351-2 1:CAS:528:DC%2BC3cXkslakt7Y%3D
8. S Chiavassa I Aubineau-Lanièce A Bitar A Lisbona J Barbet D Franck JR Jourdain M Bardiès 2006 Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code Phys Med Biol 51 3 601 616 16424584 10.1088/0031-9155/51/3/009 1:STN:280:DC%2BD28%2FjslWlsA%3D%3D (Pubitemid 43139107)
9. GD Flux S Webb RJ Ott SJ Chittenden R Thomas 1997 Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging J Nucl Med 38 7 1059 1066 9225791 1:STN:280: DyaK2szmvFejsQ%3D%3D (Pubitemid 27339611)
10. EE Furhang CS Chui KS Kolbert SM Larson G Sgouros 1997 Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy Med Phys 24 7 1163 1172 9243479 10.1118/1.598018 1:STN:280:DyaK2szoslCntA%3D%3D (Pubitemid 27306639)
11. KS Kolbert G Sgouros AM Scott JE Bronstein RA Malane J Zhang H Kalaigian S McNamara L Schwartz SM Larson 1997 Implementation and evaluation of patient-specific three-dimensional internal dosimetry J Nucl Med 38 2 301 308 9025759 1:STN:280:DyaK2s7nvVeltA%3D%3D (Pubitemid 27061616)
12. TM Behr RM Sharkey G Sgouros RD Blumenthal RM Dunn K Kolbert GL Griffiths JA Siegel WS Becker DM Goldenberg 1997 Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry Cancer 80 12 Suppl 2591 2610 9406714 10.1002/(SICI)1097-0142(19971215)80:12+<2591::AID- CNCR35>3.0.CO;2-5 1:CAS:528:DyaK1cXht1Krsw%3D%3D (Pubitemid 28009516)
13. M Tagesson M Ljungberg SE Strand 1996 A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system Acta Oncol 35 3 367 372 8679268 10.3109/ 02841869609101653 1:STN:280:DyaK283nvFKrsQ%3D%3D (Pubitemid 26201759)
14. Sgouros G, Kolbert KS, Zaidi H. The three-dimensional internal dosimetry software package, 3D-ID. In: Therapeutic applications of Monte Carlo calculations in nuclear medicine. Philadelphia: Institute of Physics; 2002.
15. KS Kolbert KS Pentlow JR Pearson A Sheikh RD Finn JL Humm SM Larson 2007 Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software J Nucl Med 48 1 143 149 17204711 1:CAS:528:DC%2BD2sXhvFKmtro%3D (Pubitemid 47555388)
16. G Sgouros G Barest J Thekkumthala C Chui R Mohan RE Bigler PB Zanzonico 1990 Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides J Nucl Med 31 11 1884 1891 2231006 1:STN:280:DyaK3M%2FjvVegug%3D%3D (Pubitemid 20374529)
17. R Mohan G Barest LJ Brewster CS Chui GJ Kutcher JS Laughlin Z Fuks 1988 A comprehensive three-dimensional radiation treatment planning system Int J Radiat Oncol Biol Phys 15 2 481 495 3403328 10.1016/S0360-3016(98)90033-5 1:STN:280:DyaL1c3pvVenug%3D%3D
18. AR Prideaux H Song RF Hobbs B He EC Frey PW Ladenson RL Wahl G Sgouros 2007 Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry J Nucl Med 48 6 1008 1016 17504874 10.2967/jnumed.106.038000 (Pubitemid 46909931)
19. JF Fowler 2010 21 years of biologically effective dose Br J Radiol 83 991 554 568 20603408 10.1259/bjr/31372149 1:STN:280:DC%2BC3cnkvVWktA%3D%3D
20. JA O'Donoghue 1999 Implications of nonuniform tumor doses for radioimmunotherapy J Nucl Med 40 8 1337 1341 10450686 (Pubitemid 29385643)
21. R Dale 2004 Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy Cancer Biother Radiopharm 19 3 363 370 15285884 10.1089/1084978041425070 (Pubitemid 38924502)
22. R Dale A Carabe-Fernandez 2005 The radiobiology of conventional radiotherapy and its application to radionuclide therapy Cancer Biother Radiopharm 20 1 47 51 15778580 10.1089/cbr.2005.20.47 1:CAS:528: DC%2BD2MXisVSht7o%3D (Pubitemid 40478521)
23. RG Dale 1985 The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy Br J Radiol 58 690 515 528 4063711 10.1259/0007-1285-58-690-515 1:STN:280:DyaL28%2Flt1arsw%3D%3D (Pubitemid 15018411)
24. S Baechler RF Hobbs AR Prideaux RL Wahl G Sgouros 2008 Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry Med Phys 35 3 1123 1134 18404947 10.1118/1.2836421 (Pubitemid 351322658)
25. RF Hobbs G Sgouros 2009 Calculation of the biological effective dose for piecewise defined dose-rate fits Med Phys 36 3 904 907 19378750 10.1118/1.3070587
26. RF Hobbs RL Wahl MA Lodge MS Javadi SY Cho DT Chien ME Ewertz CE Esaias PW Ladenson G Sgouros 2009 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison J Nucl Med 50 11 1844 1847 19837771 10.2967/jnumed.109.066738
27. M Zaider L Hanin 2007 Biologically-equivalent dose and long-term survival time in radiation treatments Phys Med Biol 52 20 6355 6362 17921589 10.1088/0031-9155/52/20/017 (Pubitemid 350093198)
28. LS Freudenberg W Jentzen SP Müller A Bockisch 2008 Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET Eur J Nucl Med Mol Imaging 35 3 502 508 18026950 10.1007/s00259-007- 0601-4 1:CAS:528:DC%2BD1cXjvFOgt7k%3D
29. KS Kolbert KA Hamacher JG Jurcic DA Scheinberg SM Larson G Sgouros 2001 Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia J Nucl Med 42 1 27 32 11197975 1:CAS:528:DC%2BD3MXhtF2nsb0%3D (Pubitemid 32104773)
30. MG Stabin RB Sparks 2003 OLINDA: PC-based software for biokinetic analysis and internal dose calculations in nuclear medicine J Nucl Med 44 5 103P
31. MG Stabin RB Sparks E Crowe 2005 OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine J Nucl Med 46 6 1023 1027 15937315 (Pubitemid 43733519)
32. 131I-tositumomab therapy. J Nucl Med 2010;51(4):654-9.
33. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med 2010;51(7):1155-62.
34. HR Maxon EE Englaro SR Thomas VS Hertzberg JD Hinnefeld LS Chen H Smith D Cummings MD Aden 1992 Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients J Nucl Med 33 6 1132 1136 1597728
35. SR Thomas HR Maxon JG Kereiakes 1976 In vivo quantitation of lesion radioactivity using external counting methods Med Phys 03 04 253 255 958163 10.1118/1.594287 1:CAS:528:DyaE28XltFyrt7w%3D